Kuros receives European Patent for fibrin-based biomaterial-biologic combination products
Kuros Biosurgery AG announced that it has received allowance of its European patent application, EP 1124590. The patent application, which was in-licensed from California Institute of Technology (Caltech) covers Kuros’ technology related to the incorporation of bioactive factors into fibrin matrices. It is core to the portfolio of intellectual property that covers Kuros’ novel biomaterial and biologic combination products.
Allowance of this patent application enhances protection of Kuros’ fibrin-based technologies and of many of its fibrin-based programs including its leading clinical stage programs, such as KUR-111 for tibial plateau fractures, KUR-113 for tibial shaft fractures, and KUR-212 for mesh grafting in burns patients. All of these programs are currently in Phase II clinical testing.
Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The company’s product candidates are based on one of two different matrix technology platforms; fibrin or synthetic biomaterial matrices. Allowance of this patent application strengthens Kuros’ position in the development of therapeutic products based on the addition of drugs into fibrin matrices.
EP 1124590 is the European counterpart of already granted US patents US 6,331,422 & US 6,607,740.
Other news from the department research and development
